Healio

Sickle cell disease increases risk for transplant-associated thrombotic microangiopathy

Please provide your email address to receive an email when new articles are posted on . SALT LAKE CITY — Sickle cell disease increased risk for transplant-associated thrombotic microangiopathy among ...
Business Wire

Omeros Corporation Announces Upcoming Presentations Detailing Outcomes of Narsoplimab Treatment for TA-TMA Under an Expanded Access Program

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced two presentations that will be featured at the 2025 Tandem Meetings – the Transplantation & Cellular Therapy Meetings of the ...
Business Wire

Report of Successful OMS721 Treatment of Patient with Both Stem Cell Transplant-Associated Thrombotic Microangiopathy and Graft-versus-Host Disease Presented at EBMT Annual ...

The patient was a participant in Omeros’ ongoing Phase 2 uncontrolled clinical trial of thrombotic microangiopathies, including HCT-TMA. To be eligible for enrollment, HCT-TMA patients are required to ...
Nasdaq

Omeros Wins FDA Approval For YARTEMLEA In Transplant-Associated Thrombotic Microangiopathy

(RTTNews) - Omeros Corporation (OMER) today announced that the FDA has approved YARTEMLEA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy in adults and ...
Morningstar

Omeros Announces Publication Highlighting Survival Benefits in TA-TMA Patients Treated with Narsoplimab Versus a Well-Matched External Control Group

Omeros Corporation (Nasdaq: OMER) today announced the publication of a peer-reviewed manuscript in Blood Advances, a journal of the American Society of Hematology,detailing survival outcomes in adult ...
EurekAlert!

Complement protein Ba levels indicate transplant-associated thrombotic microangiopathy

Transplant-associated thrombotic microangiopathy (TA-TMA) is a fatal complication that can occur after an allogeneic hematopoietic stem cell transplantation (allo-HSCT). Study finds that despite ...
Nasdaq

Omeros Submits Narsoplimab Marketing Authorization Application to the European Medicines Agency for the Treatment of TA-TMA

SEATTLE--(BUSINESS WIRE)-- Omeros Corporation (Nasdaq: OMER) today announced the recent submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for narsoplimab ...
Stocktwits on MSN

OMER stock gains ground as commercial rollout of Yartemlea exceeds expectations

Operating expenses fell in Q1 after Omeros sold its experimental drug Zaltenibart asset to Novo Nordisk in the latter half of 2025 for up to $2.1 billion. ・Omeros is now awaiting a European Medicines ...